Supplement Insider Evidence-based wellness
Ingredients / Lutein & zeaxanthin
Strong evidence overall 11 articles · reviewed 2 Sep 2026

Lutein & zeaxanthin

Carotenoids from Tagetes erecta

Two carotenoids that concentrate in the macula. Among the few eye-health ingredients with long-term outcome data rather than surrogate markers.

What the evidence supports

Strong Macular pigment density Dose-dependent increases across many trials, measurable within 12–24 weeks.
Strong AMD progression The AREDS2 trial supported a reduced rate of progression to advanced AMD in higher-risk participants.
Moderate Glare & contrast Improved photostress recovery and contrast sensitivity in several small trials of healthy adults.
Limited Screen-related eye strain Symptom questionnaires improve modestly, but blinding is weak and trials are short.
Dose used in trials
10 + 2 mg

per day of lutein and zeaxanthin respectively — the AREDS2 ratio, taken with a fat-containing meal.

Safety
Well tolerated

Harmless skin yellowing at very high intakes is the only common report.

Ask a doctor first if
Two cases

Existing retinal disease under specialist care, or smoking with beta-carotene in the same formula.

The trials, individually

Open any one for sample size, funding and what it actually measured.

AREDS2 · 4,203 adults · AMD progression
Multi-centre, randomised, five years. Replacing beta-carotene with lutein/zeaxanthin lowered progression to advanced AMD, with the clearest benefit in the lowest-dietary-intake quintile. Publicly funded.
Nolan et al. · 105 adults · pigment density
Twelve months, three carotenoid formulations. Macular pigment optical density rose in all active arms; contrast sensitivity followed in the higher-dose group.
Meta-analysis · 20 trials · visual function
Consistent effect on pigment density, inconsistent translation to self-reported vision. Heterogeneous dosing and outcomes limit pooling.

Related reading